ACIP publishes 2017–18 influenza vaccination recommendations – APhA submits compounding comments to FDA.

26799_graphic_standard_080816Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

ACIP publishes 2017–18 influenza vaccination recommendations – APhA submits compounding comments to FDA. – (866) 348-2889

CDC’s Advisory Committee on Immunization Practices (ACIP) has published its recommendations for this season’s influenza immunization in the August 25 Morbidity and Mortality Weekly Report. As in previous years, ACIP continues to recommend annual influenza immunization for all people age 6 months or older, and that immunization providers offer the immunizations before the end of October. Children ages 6 months through 8 years who need 2 doses should receive their first dose as soon as the vaccine becomes available so they may receive their second dose by the end of October.

The report notes the composition of the 2017-18 influenza vaccinations. The U.S. 2017-18 trivalent influenza vaccines contain A/Michigan/45/2015 (H1N1)pdm09–like virus, an A/Hong Kong/4801/2014 (H3N2)–like virus, and a B/Brisbane/60/2008–like virus (Victoria lineage). The additional virus strain in quadrivalent vaccines is a B/Phuket/3073/2013–like virus (Yamagata lineage), which is a change in the influenza A(H1N1)pdm09 virus component from last season.

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.